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Summary 
The Duffy antigen/receptor for chemokines (DARC), first identified on erythrocytes, functions 
not only as a promiscuous chemokine receptor but also as a receptor for the malarial parasite, 
Plasmodium  vivax. The recent finding that DARC is ubiquitously expressed by endothelial cells 
lining postcapillary venules provides a possible insight into the function of this receptor because 
this anatomic site is an active interface for leukocyte trafficking. However, the biological significance 
of DARC is questionable since it has not yet been determined whether individuals lacking the 
expression of this protein on their erythrocytes (Duffy negative individuals), who are apparently 
immunologicaUy normal, express the receptor on endothelial cells. However, we report here that 
DARC is indeed expressed in endothelial cells lining postcapillary venules and splenic sinusoids 
in individuals who lack the erythrocyte  receptor. These findings are based on immunohistochemical, 
biochemical, and molecular biological analysis of tissues  from Duff-y negative individuals. We 
also present data showing that, in contrast to erythrocyte DAILC, cells transfected with DARC 
internalize radiolabeled ligand. We conclude that the DARC may play a critical role in mediating 
the effects of proinflammatory chemokines on the interactions between leukocyte and endothelial 
cells since the molecular pathology of the Duffy negative genotype maintains expression on the 
latter cell type. 
C 
hemokines are a family of proinflammatory molecules 
involved in immunoregulatory and inflammatory pro- 
cesses (1, 2) that specifically chemoattract and activate leuko- 
cytes (1). Chemokines can be divided into two families based 
on whether the first two cysteines are juxtaposed (C-C) or 
separated by a single amino add residue (C-X-C) (2). In general 
members of the C-X-C branch, which include IL-8 and mela- 
noma growth-stimulating activity (MGSA), 1 preferentially 
activate neutrophils, whereas C-C chemokines, which include 
RANTES and monoc3rte chemotactic protein 1 (MCP-1), exert 
more prominent effects on monocytes (2,  3). 
1 Abbreviations used in this paper: DAILC, Duffy antigen/receptor for 
chemokines;  MCP-1, monocyte  chernotactic  protein 1; MGSA, melanoma 
growth-stimulating activity. 
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The effects of chemokines on target cells  are mediated 
through specific, high affinity receptors on the cell surface 
(4, 5). Although these specific receptors may bind more than 
one chemokine within the C-X-C or C-C family, they do 
not crossreact, i.e.,  the C-X-C receptors do not bind C-C 
chemokines and vice versa. However, we have recently charac- 
terized a promiscuous human erythrocyte  chemokine receptor 
that binds both C-X-C and C-C chemokines with high affinity 
(6, 7). This receptor has subsequently been shown to be iden- 
tical to the Duffy blood group antigen (8-10), which is the 
erythrocyte receptor for invasion by Plasmodium  vivax  (11). 
Individuals in West Africa, which is endemic for P. vivax in- 
fection, are negative for this blood  group  antigen,  as are 
m70%  of African Americans (12). 
Since we have recently shown that  the Duffy antigen/ 
receptor for chemokines (DAKC) is expressed on endothelial 
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receptor may be involved in leukocyte trafficking. However, 
the physiological relevance of DARC to leukocyte trafficking 
is unclear since individuals lacking expression of the Duffy 
red blood cell antigen seem to have normal immune func- 
tions. One possible explanation for these observations is that 
the major biological role of DAR.C is unrelated to its expres- 
sion on erythrocytes and that it is the endothelial DAKC 
that is more physiologically important. To address this issue 
we carried out experiments to determine whether DARC 
was expressed in the endothelial cells of Duffy negative indi- 
viduals.  Here we present data from immunohistochemical 
studies that confirm that DARC is expressed on the corre- 
sponding subset of endothelial cells of Duffy negative indi- 
viduals.  This is further supported by biochemical analysis of 
membranes from the spleen of a Duffy negative individual 
which confirmed the expression of DARC. Investigations of 
receptor function using  transfectants revealed  that DARC 
bound and internalized ligand, whereas the latter function 
could not be demonstrated in  erythrocytes. Overall these 
findings suggest that DARC  is involved in mediating the 
effects of proinflammatory chemokines on endothelial cells 
lining postcapillary venules. 
Materials and Methods 
Materials.  12sI-IL-8 and  12SI-MGSA (specific activity  2,200 
Ci/mmol) were obtained from New England Nuclear (Boston, 
MA). Unlabeled II_-8 and MGSA were purified as previously de- 
scribed (6, 14). R.ANTES and MCP-1 were from Peprotech (Prince- 
ton, NJ). Enriched human erythrocytes from outdated blood were 
obtained from Peninsula Blood Bank (Burlingame, CA). Reagents 
for dectrophoresis were from Bio-Rad Labs. (Richmond, CA) and 
FMC Corp. (Rockland, ME). All other reagent grade chemicals 
were from Sigma Chemical Co. (St. Louis, MO). The Fy6 mAb 
to the Duffy blood group antigen was kindly provided by Dr. M. 
Nichols (Abbott Labs., Chicago, IL) as a hybridoma culture super- 
natant  containing 22/~g per ml of IgG (15). 
Immunohistochemistry.  Tissue  blocks were  obtained from the files 
of the University of  Louisville  Hospital. Sections were cut at 6/~m, 
deparaffmized with xylene, and rehydrated with ethanol.  After 
washing with PBS, slides were incubated with Fy6. Binding of 
the monoclonal antibody was detected by sequential incubations 
with a biotinylated secondary antibody, followed by complexes of 
avidin-biotinylated peroxidase. The reaction product was localized 
by incubation with the diaminobenzidine substrate. 
Procurement of Human Tissue.  Human tissues were obtained at 
the University of Louisville Hospital according to a standard pro- 
tocol by which the operative consent form includes permission that 
the tissue can be used for research purposes after being thoroughly 
examined by the pathologist responsible for diagnostic evaluation 
of the specimen. 
Isolation of Erythrocytes and Production of  Erythrocyte Ghosts.  Hu- 
man erythrocytes were isolated from whole blood using standard 
techniques (16). Erythrocyte ghosts  were prepared as described 
previously (6). 
Pre~ration of CellMembranes.  Human spleen from a Duffy nega- 
tive individual (3.5 g) was homogenized in 50 mM Tris-HC1 buffer, 
pH 7.4, containing 5/zg/ml each of leupeptin and aprotinin, 0.1 
mM PMSF, 0.05 mM Pefabloc, and 1 mM EDTA (lysis buffer). 
The homogenate was centrifuged at 500 g for 20 min. The pellet, 
which consisted of cell debris and nuclei, was discarded and the 
supernatant was centrifuged at 48,000g for 30 min. The resulting 
pellet, which consisted of total cell membranes was removed and 
resuspended to a final concentration of 5.5 mg per ml in lysis  buffer 
and stored at  -20~  until further use. 
12SI-Labeled Chemokine  Binding  to Duffy Negative  Spleen Mem- 
branes.  Human spleen membranes from a Duffy negative individual 
(50/~g) were incubated with  l~I-labeled MGSA (0.5 nM)  and 
varying concentrations of unlabeled MGSA at 4~  for 1 h in PBS, 
pH 7.4. Binding was stopped by filtration through Whatman GF/C 
filters pretreated  with  1%  polyethyleneimine (Whatman  Inc., 
Clifton, NJ). Filters were rinsed three times with 2 ml of ice-cold 
PBS and counted in a gamma counter (Iso-Data 100; Isodata, Costa 
Mesa, CA). Nonspecific binding was determined in the presence 
of 100 nM unlabeled ligand. Binding data were analyzed by the 
Ligand program  (17) as modified for the IBM PC (18). 
Internalization of l25I-labeled MGSA in K562 Cells Transfected with 
the DARC eDNA.  106 cells per ml were incubated with nSI-la- 
beled MGSA in the presence and absence of unlabeled MGSA at 
4~  and at 37~  for the designated times. Aliquots were removed 
from each tube and the suspension centrifuged at 12,000 g for 1 
rain to sediment the cells. After discarding the supernatants the 
cell pellets were resuspended either in ice-cold PBS or in acidic 
media (PBS, pH 3) for 2 rain. The incubation was terminated by 
removing aliquots from the cell suspension and separating cells 
from buffer by centrifugation  through a silicon/parat~n oil mix- 
ture as described previously (19). Non-specific binding was deter- 
mined in the presence of 1/zM unlabeled MGSA. Treatment of 
cells incubated at 4~  with acidic buffer resulted in the displace- 
ment of >95% of the bound counts and yielded an estimate of 
total cell surface  binding. Cell-associated  radioactivity was then de- 
termined by acid extraction of cells at 37~  which removed the 
cell surface-bound material and thus gives a measure of the inter- 
nalization of the ligand. 
Immunoblot Analysis.  Proteins were subjected to etectrophoresis 
in 12% Novex precast minigels and transferred electrophoretically 
to Problot (Applied Biosystems Inc., Foster City, CA) in 10 mM 
CAPS (3-[cyclohexolamino]-l-propane sulfonic acid), pH 11, con- 
taining 10% methanol for 1 h at a current of  250 mA. After transfer, 
the blots were incubated for 60 rain at room temperature in 25 mM 
Tris-HC1, pH 7.4, containing 150 mM NaC1 and 0.1% Tween 20. 
The blots were then incubated overnight at 4~  with a 1:1,000 
dilution of Fy6. The blots were washed several  times in Tris buffer 
and subsequently incubated in a 1:20,000 dilution of horseradish 
peroxidase-conjugated  goat anti-mouse antibody (Tago Inc., Bur/fin- 
game, CA) for I h at room temperature. After extensive washing, 
the blots were developed  by ECL, according to the manufacturer's 
instructions  (Amersham Corp.,  Arlington  Heights,  IL). 
Cross-linking of ~2SI-MGSA to Cell Membranes.  Aliquots of the 
particulate membrane function (150  #g) were incubated in the pres- 
ence of 5 nM of 125I-MGSA, in the presence or absence of I/zM 
unlabeled MGSA, for 1 h at 4~  in PBS, pH 7.4. At the end of 
the incubation,  the membranes were pelleted by centrifugation 
(100,000 g, for 15 min), made up to the original volume in PBS, 
and chemically  cross-linked  with EDC (1, ethyl-3-[3-dimethamino- 
propyl]carbodiimide hydrochloride), at  a final concentration  of 
I mM for 1 h at room temperature. The membranes were then 
pelleted as described above and solubilized in SDS sample buffer 
in the presence of 50 mM dithiothreitol  (DTT) for 3 min at room 
temperature  and then analyzed by electrophoresis in  12% Tris- 
glycine polyacrylamide gels containing  SDS. 
Northern Blot Analysis.  Pieces  of human spleen were extracted 
with guanidinium isothiocyanate (20) and total cellular RNA was 
1312  Red Cell-specific Promiscuous Chemokine Receptor Deficiency Figure  1.  Immunohistochemical  localization and Northern blotting of DARC in endothelial cells of postcapiUary venuhs in spleen. (A) DARC 
is expressed by endothelial cells lining sinusoids of splenic red pulp. The spleen from a Duffy positive  individual was stained with Fy6 and counterstained 
with hematoxylin (x 409). There is strong immunoreactivity with specialized endothelial cells 1;nlng the sinusoids. Hemosiderin-laden macrophages 
in the background have an amber color. (B) Endothelial cells lining postcapillary venules in Duffy negative individuals express DARC. Subcutaneous 
tissues from a Duffy negative woman who underwent mastectomy  for mammary  carcinoma  were analyzed  for DARC expression  by immunohistochemistry. 
Para~n-embedded tissues were processed as described under experimental procedures. Endothelial cells lining thin-walled venules demonstrated high 
level expression  whereas erythrocytes  in the lumena of  the vessels  lacked  immunoreactivity.  (C) Spleen from Duffy negative individuals expresses DARC 
mRNA transcripts. Total RNA was extracted from the spleen of a Duffy negative individual who underwent autopsy examination (lane 1) and the 
human erythrolenkemia  (HEL) cell line (lane 2) and separated by size  in agarose  gels containing formaldehyde.  Northern blotting analysis  with a radiola- 
baled DARC eDNA probe demonstrated that both RNA samples contained a mRNA transcript of ,'~1,300 bp. The mobility of RNA of standard 
size is indicated on the left (from top, 4,400, 3,370, 1,350, and 240 bp). 
quantitated by measuring the absorbance at 260 nm. Aliquots of 
tLNA were subjected to electrophoresis  in a 1.2% agarose gel con- 
taining 20 mM MOPS, 5 mM sodium acetate,  5 mM EDTA, and 
6% formaldehyde.  The size-fractionated  RNA was transferred  to 
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a nylon membrane. A eDNA probe spanning the coding sequences 
of DARC (21) was labeled with cr  (3000/zCi/mMol) 
using random hexanuchotide primers.  The probe was aUowed to 
hybridize to the membrane overnight at 42~  in the presence of 50% formamide. Blots were washed under stringency conditions 
(55~  in 0.1x  SSC, 0.1%  SDS). 
Nucleotide Sequence Analysis of the DARC Gene.  Segments of 
the gene encoding DARC (21) were amplified by PCR. Genomic 
DNA served as templates in standard PCR amplification reactions 
containing sense and antisense oligonucleotide primers designed 
from untranslated sequences  upstream (5'TTCCCAGGAGAC'IUT- 
TCCGGT) and downstream (5'ACqTEKATTCAGGTTGACAGG- 
TGGG) of the exon encoding the DAKC polypeptide, respectively. 
The resulting amplification product of ,o1,100 bp was subcloned 
into the TA vector (Invitrogen, San Diego, CA). The nucleotide 
sequence  was determined using a Sequenase  kit (United States Bio- 
chemicals Corp., Cleveland, OH) with universal forward and re- 
verse primers that anneal to sites in the vector and with primers 
corresponding to DARC-coding sequences  at intervals  of,o300 bp. 
Results and Discussion 
We previously showed, by immunohistochemical analysis 
of archival tissues  and a monoclonal antibody to the Duffy 
antigen (15),  the expression of DARC  to endothelial cells 
lining small, thin-walled blood vessels characteristic of post- 
capillary venules in the kidney (13). Furthermore DARC was 
expressed on endothelial cells of small venules in all tissues 
examined except for liver. Specialized endothelial cells lining 
splenic sinusoids expressed high levels of DARC (Fig.  1 A), 
whereas those lining hepatic sinusoids were lacking activity. 
To gain insight into the physiological significance of DARC 
in individuals lacking expression of this protein on erythro- 
cytes, tissues  from a Duffy negative patient were examined 
for DARC expression by immunohistocbemistry. As shown 
in Fig. 1 B, DARC was expressed on endothelial cells lining 
post-capillary venules present in soft tissues, whereas erythro- 
cytes within the lumen failed to show binding of the mAb 
as expected. To further examine the expression of DARC in 
Duffy negative individuals, Northern blotting analysis was 
performed. RNA extracted from the spleen of a Duff  y  nega- 
tive individual contained an mRNA transcript of •  1,300 bp 
that annealed to a radiolabeled DARC cDNA probe (Fig. 
1 C) similar to that expressed in HEL cells  (22). 
Since spleen expressed high levels of DARC, ligand binding 
and immunoblotting experiments were carried out to corrob- 
orate this observation using splenic tissue obtained from the 
autopsy examination of a Duffy negative individual. Receptor 
binding asssays using membrane fractions prepared from the 
Duffy negative spleen demonstrated a promiscuous chemo- 
kine binding profile characteristic of DARC (4);  12SI-MGSA 
binding was completely displaced by excess unlabeled MGSA, 
IL-8, RANTES, and MCP-1. As expected, this spectrum of 
chemokine binding, which is not a feature of the other four 
known chemokine receptors (i.e., type A or B IL-8 receptor, 
RANTES/MIP-lot receptor, or the MCP-1 receptor) (23--26), 
was inhibited by the Fy6 monodonal antibody to DARC, 
but not by a monoclonal antibody to the type A IL-8 receptor 
(Fig.  2 A).  Scatchard analysis  of mI-MGSA binding (Fig. 
2 B) revealed high affinity binding, similar to that of  DARC 
expressed by (Duffy positive) erythrocytes (6, 7) and (renal) 
endothelial cells  (D), KD ~3  riM. 
Additional characterization of this receptor was undertaken 
by chemical cross-linking experiments using the Duffy negative 
Figure 2.  lzSI-MGSA  binding to human  spleen  membranes.  (A) Inhi- 
bition of nSI-MGSA  binding to human spleen membranes.  Membranes 
(50 #g) were  incubated  with 500 pM radiohbeled  MGSA in the presence 
of 100 nM unlabeled  MGSA, II-8, RANTES, MCP-1, and MIP-lot. The 
binding reactions  were  stopped  as described  under  Materials  and.Methods. 
Data are from  three  separate  experiments  and the error  bars show  the SEM. 
(/3) Scatchard  analysis  of 12SI-MGSA  binding to human  spleen membranes. 
Membranes  (50 #g) were  incubated  with 500 pM radiohbeled  MGSA in 
the presence  of increasing  concentrations  of unlabeled  MGSA at 4~  for 
I h. Binding  was terminated  by filtration  and counted  as described  under 
Materials and Methods. 
splenic membrane fractions previously used for the ligand 
binding assays (Fig. 3). Cross-linking with radiohbeled MGSA 
revealed a labeled protein with a molecular mass of 48 kD. 
Assuming a molecular mass of  8 kD for MGSA and one ligand 
molecule per receptor, a molecular mass of 40 kD is deduced 
for the receptor. This is consistent with the reported molec- 
ular mass of DARC (6, 7, 13). Since ligand binding activity 
of the receptor was blocked by Fy6, immunoblotting was 
performed to confirm the molecular mass of this protein (Fig. 
4). A protein of similar molecular mass (*40 kD) is evident 
in  lanes  containing  membrane fractions  from  spleen  and 
erythrocytes (RBC). 
To gain insight into the mechanism responsible for DARC 
expression in Duffy negative individuals, the genomic locus 
encoding DARC was amplified from DNA templates using 
primers designed from sequences in the 5' and Y  untrans- 
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Figure  3.  Covalent  cross-linking of 
12SI-MGSA to human  spleen  membranes.  ~  3000 
Membranes prepared from  human  spleen 
(150/~g) were incubated  with 5 nM 12sI-  -o  Z500 
MGSA in the absence (lane 1) and pres- 
ence (lane  2) of I #M unlabeled  MGSA.  "~  2000 
After 1 h at 4~  the membranes  were 
washed  free of  unbound  label. The bound  ~- 
12SI-MGSA was crossqinked  by incuba-  ~  1500 
tion with EDC for 1 h at room  tempera-  :E 
ture and then washed with PBS before  ~  100o 
analysis by SDS-PAGE. Aliquots  of 150 
#g of protein were applied to the gel.  500 
After dectrophoresis  the gels were dried 
down and subjected  to autoradiography.  0 
lated regions of KNA transcripts by PCR. Electrophoretic 
analysis of PCK products revealed an identical size to that 
obtained when mRNA was reverse transcribed and cDNA 
served as templates in PCR reactions with the same primers. 
Nucleotide sequence analysis of amplification products from 
the genomic templates from a Duffy positive individual re- 
vealed that the polypeptide was encoded by a single, uninter- 
rupted exon. Parallel nucleotide sequence analysis of multiple 
clones of DNA amplification products from a Duffy nega- 
tive individual did not reveal any differences  in coding se- 
quence  compared  to  that  of a  Duffy positive  individual. 
Nudeotide sequence analysis of multiple clones revealed two 
sequences that differed only in the second nucleotide of codon 
44.  Approximately half of the clones from the Duffy posi- 
tive individual analyzed contained GAT and the remainder 
contained GGT, which encode aspartic acid and glycine resi- 
dues, respectively.  These differences in sequence could con- 
stitute the difference between the Duffy A and B blood groups. 
In common with other cloned chemokine receptors  (5), 
genomic sequences encoding DAKC lack introns. Since the 
predicted primary structure of DARC is identical in Duffy 
positive and negative individuals it is concluded that the mech- 
anisms responsible for silencing the expression  of DAKC in 
erythroid cells are not related to a defect in the coding se- 
quence. Since mRNA transcripts are absent from erythroid 
Figure  4.  Western blot analysis of 
human spleen membranes. Call mem- 
branes (150/~g) from a Duffy negative 
spleen (lane 1) and Duffy  positive  eryth- 
rocyte ghosts (lane  2) were subjected  to 
SDS-PAGE, transferred  dectrophoretically 
to Problot, and analyzed as  indicated 
under Materials and Methods. 
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Figure  5.  The time course of internalization  of t2SI-MGSA  by K562 
cells transfected  with DAKC. Cells were incubated  with t2SI-MGSA at 
37 and 4~  Aliquots  were  removed  at the times  indicated,  cooled  to 4~ 
and acid stripped with PBS, pH 3, for 2 min to dissociate  surface  bound 
ligand. Bound  ligand  was separated  from free  by centrifugation  through 
oil as described above. Data are expressed as cpm of 12SI-MGSA  that were 
internalized. Internalized ligand was calculated by subtracting specific 
binding in cells (incubated  at 37~  that were acid stripped from those 
that were not. Add stripping of cells incubated  at 4~  decreased  specific 
binding by greater than  95% which  is a direct measure  of the efficiency 
of this method.  Data shown are representative  from  two separate  studies. 
dements in Duffy negative individuals (21), we speculate that 
this mechanism may involve c/s-acting  sequences  that con- 
trol transcription of this gene in erythroid cells. This has been 
previously described in selected cases of hereditary elliptocy- 
tosis in which isoform-specific  mutations result in complete 
deficiency of protein 4.1 in erythrocytes  but not nonerythroid 
cells (27). 
Taken together these immunohistochemical, biochemical, 
and genetic data establish  that DARC is expressed  by en- 
dothelial cells lining postcapiUary venules in Duffy negative 
individuals. The receptor demonstrated a promiscuous chemo- 
kine binding profile and had the same molecular weight de- 
scribed for DARC. These findings suggest that a DARC pro- 
tein identical to that present in Duffy positive individuals 
is expressed on endothelial cells when the negative selection 
from morbidity and mortality from P. vivax resulted in the 
abrogation of expression of this protein by erythrocytes. This 
dichotomous expression in Duffy negative individuals raises 
the possibility that DARC plays an essential role in the bi- 
ology of endothelial cells, whereas its function on erythro- 
cytes appears  to be dispensable. 
At least  four formal biologic mechanisms of action sug- 
gest themselves for this receptor. They include: (a) a signaling 
receptor,  (b) a chemokine transporter, (c) an accessory, pre- 
senting  receptor,  and  (d)  a  sink  for  the  inactivation  of 
chemokines. Preliminary experiments were carried out to ex- 
plore these possibilities.  One feature that characterizes  both 
signaling receptors  and chemokine transporters is the inter- 
nalization of  bound ligands. The ability of  DARC K562 trans- 
fectants to internalize radiolabeled chemokines is shown in 
Fig. 5. Rapid internalization of 12SI-MGSA is evident and by 3 h,  almost 40%  of the bound label is internalized.  SDS- 
PAGE analysis  of the internalized  chemokine over time re- 
vealed that it remained intact (data not shown). Collectively, 
these functional studies suggest that DARC may have a sig- 
naling and/or transporter-like role, but that it lacks features 
associated with a ligand-presenting receptor subunit. Whereas 
Duffy positive erythrocytes were shown to function as a sink 
for  ligand  this  may  not  reflect  the  central  physiological 
significance  of the receptor because the absence of this func- 
tion in Duffy negative individuals is not associated with any 
apparent  abnormality of chemokine activity.  The  findings 
presented here demonstrate  the preservation of DARC ex- 
pression by endothelial cells lining postcapillary veuules and 
splenic sinusoids in individuals negative for the Duffy blood 
group antigen, who could be considered Nature's experiment 
that abrogated expression of this receptor on erythrocytes to 
provide protection from malaria induced by P. vivax.  This 
suggests that DARC is a biologically relevant receptor that 
could play a key role in inflammation and leukocyte trafficking 
at  these active interfaces of circulation. 
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